Clinical trials: Non-small Cell Lung Cancer, Squamous or Non-squamous
Non-squamous Non-small-cell Lung Cancer
Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.
This study will compare maintenance therapy with anlotinib plus pemetrexed versus pemetrexed or anlotinib alone, in patients with Non-squamous Non-small cell lung cancer who have not progressed during first-line therapy with…
- Trial name
- NCT04453423
- Testing
- Anlotinib + Pemetrexed+Carboplatin, Pemetrexed, Anlotinib + Pemetrexed
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Squamous Non-small Cell Lung Cancer
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
This is a multi-center, open-label Phase Ib dose escalation part followed by a randomized double-blinded placebo controlled Phase II part.
- Trial name
- NCT01911325
- Testing
- Buparlisib, Docetaxel
- Where
- 16 sites in United States, Belgium and 6 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer, Squamous Lung Dysplasia
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
This randomized phase II trial is studying inositol to see how well it works compared with a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia.
- Trial name
- NCT00783705
- Testing
- inositol
- Where
- 4 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
Lung Cancer
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070486
- Testing
- carboplatin, celecoxib, gemcitabine hydrochloride
- Where
- 75 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Squamous Non-Small Cell Lung Cancer
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This open label, 2-part study will evaluate the safety and efficacy of RO5083945 in combination with standard chemotherapy in patients with advanced or recurrent non-small cell lung cancer who have not received prior…
- Trial name
- NCT01185847
- Testing
- RO5083945, cisplatin, gemcitabine
- Where
- 32 sites in Belgium, France and 5 more
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche